Microparticles As Novel Biomarkers In Liver Cancer
Funder
National Health and Medical Research Council
Funding Amount
$85,833.00
Summary
No current highly sensitive or specific diagnostic and prognostic biomarker for hepatocellular carcinoma (HCC) exists. We will identify novel nucleic acid signatures in the circulation of patients with HCC through Next Generation Sequencing. Plasma microvesicles will be isolated and their contents analyzed to identify novel genetic biomarkers and fusion gene constructs specific for HCC. Resultant panel of novel biomarkers for HCC will be validated on the Australian STREP cohort of HCC patients.
Lung cancer is the commonest cause of cancer death worldwide. There is growing interest in the genetic causes of lung cancer. The overall aim of this research is to gain a better understanding of the steps in the genetic pathway of lung cancer spread. This knowledge is essential in the development of new targeted therapies and improvement in lung cancer prognosis.
Personalised Biomarkers In Breast Cancer Using Circulating Tumour DNA
Funder
National Health and Medical Research Council
Funding Amount
$231,060.00
Summary
The measurement of tumour specific circulating DNA in the blood of women with breast cancer has the potential to be utilised as a personalised biomarker and revolutionise the management of this disease. This project aims to improve our understanding of the relationship between circulating tumour DNA, the progression of cancer, and responses to cancer treatment. Furthermore, it aims to address how this new tool can be integrated into clinical practice to provide benefits for women with breast can ....The measurement of tumour specific circulating DNA in the blood of women with breast cancer has the potential to be utilised as a personalised biomarker and revolutionise the management of this disease. This project aims to improve our understanding of the relationship between circulating tumour DNA, the progression of cancer, and responses to cancer treatment. Furthermore, it aims to address how this new tool can be integrated into clinical practice to provide benefits for women with breast cancer.Read moreRead less
A Comprehensive Genomic Analysis Of Oesophageal Adenocarcinoma: Understanding The Genetic Aetiology Of OAC Towards Biomarkers Of Progression, Prognosis And Targeted Treatment.
Funder
National Health and Medical Research Council
Funding Amount
$987,906.00
Summary
Oesophageal cancer (OAC) continues to have poor survival despite surgery, chemotherapy and radiotherapy. Selecting patients for the most appropriate therapies and improving survival remain unmet research needs. We propose to undertake a detailed genetic study of OAC, including “next generation” sequencing, in order to catalogue the genetic changes in the disease. This information forms an essential basis for identifying genetic signatures of OAC progression, prognosis and treatment response.